TLR2/6 agonists and IFNgamma induce CXCL10 from melanoma

ABSTRACT: Clinical approaches to treat advanced melanoma include immune therapies, whose benefits depend on tumor-reactive T-cells to infiltrate metastases. However, most tumors lack significant immune infiltration prior to therapy, and some immune therapies are hindered by a persistent lack of immune cell infiltration. CXCL10 has been implicated as a critical chemokine supporting T-cell migration into tumors; thus agents that induce CXCL10 in tumors may improve patient responses to systemic immune therapy. We find that melanoma cells treated with TLR2/6 agonists (MALP-2 or FSL-1) and interferon-gamma (IFNgamma) upregulate CXCL10 production, when compared to IFNgamma treatment alone or no treatment. Gene profiling of melanoma cells lines treated with TLR2/6 agonists and IFNgamma demonstrate that a s

ORGANISM(S): Homo sapiens

SUBMITTER: Francesco Marincola 

PROVIDER: E-GEOD-64506 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress